Cheapest FDA-Approved GLP-1 in 2026 (Real Prices, Verified This Month)

What we actually verified

• Every self-pay price against the manufacturer's own pricing page on April 20, 2026: NovoCare, Lilly pricing, Foundayo terms, Zepbound savings, Ro pricing, Walgreens, and TrumpRx
• Every intro-offer expiration date in the official terms
• FDA approval status and indication for each medication
• The CMS GLP-1 Bridge eligibility criteria (updated April 6, 2026)

We did not call pharmacies. We did not negotiate. Every number below is the published public self-pay price — not a private discount.

The real cost map: every FDA-approved GLP-1, every route

Entry cost = lowest published medication price + any mandatory first-step fee. Maintenance = what you'll actually pay once you titrate up to a typical weight-loss dose.

First: which route is cheapest for your situation?

Most pages give one answer to a question that actually has five answers. Pick the one that sounds like you.

Cheapest FDA-approved oral GLP-1: Wegovy pill vs. Foundayo

Wegovy pill and Foundayo are the two cheapest FDA-approved GLP-1s on the market in April 2026, both starting at $149 per month self-pay. Wegovy pill produced about 16.6% average weight loss in adherent participants in its pivotal trial; Foundayo produced about 11% at the highest dose. Foundayo is easier to take — no food or water restrictions.

Wegovy pill (oral semaglutide 25 mg) — $149/mo starting, $299/mo maintenance

FDA-approved December 22, 2025. Launched January 2026. First oral GLP-1 specifically approved for chronic weight management, and also approved to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity and established heart disease.

In clinical trials (OASIS 4 — 307 adults, 64 weeks), participants on 25 mg oral semaglutide lost an average of 16.6% of body weight (adherent estimand; 13.6% under treatment-policy estimand). Roughly one-third (34.4%) of adherent participants reached ≥20% weight loss. With commercial insurance savings card: as little as $25/month.

Where to get it: NovoCare Pharmacy (manufacturer direct), Ro, Hers, Hims, GoodRx, Walgreens Weight Management.

Foundayo (orforglipron) — $149/mo starting, $299–$349/mo maintenance

FDA-approved April 1, 2026. Shipping from LillyDirect started April 6. The only FDA-approved oral GLP-1 that can be taken any time of day, with or without food or water.

In clinical trials (ACHIEVE-1, highest dose, 72 weeks): about 11% average weight loss. With commercial insurance and the Foundayo savings card: as low as $25/month. Medicare GLP-1 Bridge (July 1, 2026+): $50/month for eligible beneficiaries — all formulations covered. Available through LillyDirect, telehealth providers, and U.S. retail pharmacies.

Side-by-side: which oral GLP-1 actually wins

Cheapest FDA-approved injection: Wegovy pen vs. Zepbound vs. Ozempic

Among weekly FDA-approved injections, the cheapest self-pay starter is Wegovy pen or Ozempic at $199/month for the first two fills — an intro offer that ends June 30, 2026. After that, both move to $349/month at lower maintenance doses. Zepbound starts at $299/month via LillyDirect's Self Pay Journey.

Wegovy pen (semaglutide 2.4 mg weekly) — $199 intro, $349 ongoing

FDA-approved for chronic weight management, cardiovascular risk reduction (SELECT trial: 20% reduction in MACE in adults with overweight/obesity and established heart disease), and MASH with moderate-to-advanced liver fibrosis.

• New self-pay patient: $199/month for first two fills (0.25 mg, 0.5 mg), through June 30, 2026
• Ongoing self-pay: $349/month for 0.25–2.4 mg; $399/month for Wegovy HD 7.2 mg
• With commercial insurance savings card: as little as $25/month if covered
• List price: $1,349.02/month

Zepbound (tirzepatide) — $299 starter via LillyDirect

FDA-approved for obesity and obstructive sleep apnea (OSA). The OSA pathway is underused — if you have diagnosed sleep apnea, that's often an easier coverage authorization than obesity alone. Produced the highest average weight loss (~21% at maximum dose) among approved GLP-1 class medications.

• Vial or KwikPen: $299/month (2.5 mg) via LillyDirect Self Pay Journey
• $399/month (5 mg), $449/month (7.5–15 mg with 45-day refill cadence)
• With commercial insurance and savings card: as little as $25/month if covered
• Medicare Bridge: $50/month copay for KwikPen (not vials)

Ozempic (semaglutide weekly, T2D indication)

FDA-approved for type 2 diabetes, chronic kidney disease in T2D, and cardiovascular risk reduction in T2D — not for weight loss. Frequently prescribed off-label for weight loss. Same active ingredient as Wegovy (semaglutide), different dose structure, different labeling.

• New self-pay: $199/month for first two fills, through June 30, 2026
• Ongoing: $349/month (up to 1 mg), $499/month (2 mg)
• Note: Ozempic pricing on Ro currently runs higher than the NovoCare intro offer — if Ozempic specifically is what you want, NovoCare direct is typically cheaper.

The four legitimate channels, compared

There are four legitimate ways to buy FDA-approved brand-name GLP-1s in 2026. Which one is cheapest depends on whether you already have a prescription, whether you want insurance handled, and whether you'll pay a platform fee.

Why Ro is our top overall pick (and when it isn't)

Ro is our primary recommendation because its current public pricing matches LillyDirect, NovoCare, and TrumpRx cash prices on Wegovy pill, Wegovy pen, Foundayo, and Zepbound KwikPen — and because it includes a free insurance concierge that handles prior-authorization paperwork. Ro is not the cheapest route if your only goal is to avoid a monthly membership fee.

What if you refuse monthly memberships? (The Walgreens route)

Walgreens Weight Management is the strongest no-subscription alternative. A reader who's already decided they want a specific medication, knows they'll pay cash, and doesn't want to talk to an insurance company gets a prescriber, a pharmacy, and published self-pay prices — with no subscription.

• Initial video visit: $49
• Follow-up visits: $49 each (only when needed)
• Wegovy pill: $149/month for the first two months under Novo Nordisk's current self-pay offer; $299/month for subsequent doses
• Wegovy pen or Ozempic pen: $199/month for the first two months through June 30, 2026; then starting at $349/month
• Zepbound KwikPen: starting at $299/month through December 31, 2026

No affiliate CTA here. If Walgreens is your fit, search "Walgreens Weight Management" and start there.

Why Sesame Care is the best FDA-approved secondary

Sesame Care is the strongest secondary telehealth option because it carries the broadest branded formulary (including Mounjaro and Saxenda), offers Costco-member pricing on Wegovy and Ozempic at $349/month, and lets you pick individual providers rather than being routed inside a single platform. Success by Sesame starts at $59/month on the annual plan or $99/month standard.

Cheapest brand-name GLP-1 with commercial insurance

With commercial insurance and a manufacturer savings card, most FDA-approved GLP-1s can drop to as low as $25/month when covered. The trick is matching the medication to the indication your plan is most likely to cover, and submitting a prior-authorization request when required.

Coverage likelihood by medication

• Wegovy pen: obesity, cardiovascular risk reduction in overweight/obesity with established CVD, or MASH with moderate-to-advanced fibrosis. Strongest coverage for readers with a documented comorbidity.
• Zepbound: obesity or obstructive sleep apnea (OSA). The OSA pathway is underused — diagnosed sleep apnea is often an easier authorization than obesity alone.
• Ozempic: type 2 diabetes, chronic kidney disease in T2D, cardiovascular risk in T2D. If you have T2D, this is the highest-coverage-odds option.
• Foundayo: obesity. Coverage policies are still forming since FDA approval was April 1, 2026.
• Wegovy pill: same indications as Wegovy pen.
• Mounjaro: type 2 diabetes.

Savings card summary

• Wegovy pen (covered): as little as $0/month
• Wegovy pill (covered): up to $100/month off the monthly price
• Zepbound pen (covered): as little as $25/month
• Ozempic (covered): as little as $25/month
• Foundayo (covered): as little as $25/month

The cheapest insurance strategy

1. Check if your plan covers any FDA-approved GLP-1 before starting a consult — Ro's free GLP-1 Insurance Coverage Checker does this in under a minute.
2. Ask your prescriber about the medication most likely to be covered under your specific situation (obesity, T2D, OSA, CVD, MASH).
3. Submit the prior-authorization request. Don't assume you're not covered without trying.
4. If denied, appeal — PA denials are frequently overturned on the first appeal. Ro's concierge handles this step.
5. If insurance won't cover, apply the manufacturer savings card to cash pay to get the maximum discount.

HSA / FSA note: FDA-approved prescription GLP-1s for obesity are generally eligible HSA/FSA expenses. Telehealth consultation fees for a prescription are usually eligible too. If you use a manufacturer savings card, HSA/FSA applies only to the remaining out-of-pocket amount after the discount — you can't reimburse the same dollars twice. Confirm with your plan administrator before filing.

Medicare GLP-1 Bridge: the $50/month path starting July 1, 2026

The CMS GLP-1 Bridge lets eligible Medicare beneficiaries access Foundayo (all formulations), Wegovy (all formulations), and Zepbound KwikPen (KwikPen only — not vials) at a $50/month copay starting July 1, 2026.

Who qualifies (any one of the following)

• BMI ≥35 at initiation, OR
• BMI ≥30 with heart failure with preserved ejection fraction (HFpEF); uncontrolled hypertension despite two antihypertensive medications; or CKD stage 3a or higher, OR
• BMI ≥27 with pre-diabetes; prior myocardial infarction; prior stroke; or symptomatic peripheral arterial disease (PAD)

What's covered

• All formulations of Foundayo (0.8 mg through 17.2 mg)
• All Wegovy formulations (Wegovy pill and Wegovy pen)
• Zepbound KwikPen only — Zepbound single-dose vials are not covered

What actually happens after the intro price

Every "$149/month" or "$199/month" headline reflects the lowest dose, not the maintenance dose. Here is what a realistic self-pay year actually costs.

The intro-offer expiration list

• Wegovy pen / Ozempic $199 intro: ends June 30, 2026 — after that, $349/month for 0.25–0.5 mg
• Wegovy pill 4 mg at $149: ends August 31, 2026 — rises to $199/month for 4 mg after that date
• Zepbound KwikPen Self Pay Journey at $299: published through December 31, 2026 — verify current terms before buying

Edge cases: generic liraglutide, oral preference, HSA/FSA

"Isn't generic liraglutide cheaper than any of this?"

The first FDA-approved generic liraglutide (a generic of Saxenda, approved for chronic weight management) is available via GoodRx at roughly $372/month starting. That's cheaper than Wegovy pen and Zepbound at maintenance. It's more expensive than Wegovy pill and Foundayo at starter doses. Generic liraglutide is a daily injection (not a weekly injection and not a pill) — the different form factor and injection frequency are a real-world adherence factor that matters for most people. If you're needle-averse and price-conscious, the oral options win.

"I refuse to inject — which FDA-approved oral GLP-1 should I take?"

Wegovy pill if you can commit to the morning empty-stomach routine. Foundayo if you need flexibility in timing and eating. Both start at $149/month. See the oral comparison section above for the full breakdown. Both are available through Ro, Hers, Hims, and manufacturer-direct — no injection required.

Can I use HSA / FSA funds?

Generally yes. FDA-approved prescription GLP-1s for obesity are eligible medical expenses, and telehealth consultation fees for a prescription are usually eligible too. If you use a manufacturer savings card, HSA/FSA applies only to the remaining out-of-pocket amount after the discount — you can't reimburse the same dollars twice. Per IRS Publication 502, confirm with your plan administrator before filing.

Why this page excludes compounded GLP-1s

Compounded GLP-1s are often cheaper per month. They are also not FDA-approved, and the FDA has ongoing concerns about unapproved GLP-1 products marketed for weight loss, including adverse event reports, salt-form active ingredient substitution, and fraudulent labeling. This page specifically covers FDA-approved options only.

For the compounded category — including which providers have clean safety records and what the price difference actually is — see our GLP-1 safety guide and Ozempic alternatives comparison.

How we verified this page

Prices verified on April 20, 2026 across: novocare.com, zepbound.lilly.com, pricinginfo.lilly.com, foundayo.lilly.com, wegovy.com, trumprx.gov, ro.co/weight-loss/pricing, forhers.com, forhims.com, sesamecare.com, and walgreens.com Weight Management. FDA.gov was the primary source for approval dates and indications. CMS Medicare GLP-1 Bridge page (updated April 6, 2026) for Bridge eligibility.

• We did not call any pharmacy or provider to negotiate. Every price is the published public self-pay price.
• First-year cost examples use FDA-label titration schedules, starter price for months 1–2 where explicitly offered, and maintenance price for months 3–12.
• Walgreens, LillyDirect, NovoCare, and TrumpRx.gov are not affiliate partners and appear on this page for completeness.
• We re-verify prices monthly — last-verified date is visible at the top of this page. If you're reading this 90 days after that date, re-verify before buying.

Frequently Asked Questions

Still not sure which GLP-1 program is right for you?

The question isn't really "what's the cheapest" — it's "what's the cheapest for your specific situation." We built a 60-second matching quiz that factors in whether you already have a prescription, your insurance situation, your preference for pill or injection, and your tolerance for monthly fees.

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. This page is informational and is not medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription. Prices verified April 20, 2026 and subject to change — we re-verify monthly. If you see a discrepancy between our listed price and what a provider currently charges, the provider's current price governs.